IBRX
Immunitybio Inc
8.40$
-2.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +16.7% | -20.6% | +10.9% | -17.9% | +5.0% | -20.7% | +32.4% | +29.1% | -3.3% | +28.8% | -2.8% | |
| – | +36.7% | -33.4% | +24.1% | -32.8% | +13.1% | -40.9% | +90.7% | +58.3% | -4.4% | +43.9% | -3.1% | |
| – | +49.2% | -49.9% | -2.2% | -13.9% | +28.1% | -57.7% | +126.9% | -56.2% | +46.6% | +132.3% | -63.1% | |
| – | +40.4% | -36.0% | +27.9% | -40.2% | +14.9% | -58.9% | +149.5% | +67.8% | -5.8% | +56.9% | -6.2% | |
| – | +36.3% | -32.5% | -3.6% | +138.1% | -45.9% | +557.9% | +27.9% | +51.0% | +26.4% | +1.5% | +23.6% | |
| – | – | – | – | +8.1% | +322.5% | +2.1% | -21.4% | +0.9% | -86.4% | -39.9% | +254.7% | |
| – | – | – | – | – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +1,200.7% | |
| – | -7.4% | -3.0% | -3.1% | -3.0% | -3.5% | -3.3% | -3.2% | -3.6% | -3.8% | -8.2% | -1.2% | |
| – | +29.3% | +0.1% | +4.6% | -2.9% | -21.4% | +2.7% | +8.7% | +7.3% | -3.9% | +51.4% | +10.5% | |
| – | -35.5% | -7.8% | +15.5% | -1.9% | -9.9% | -10.4% | +2.9% | +12.8% | +8.1% | +10.0% | +12.9% | |
| – | +20.2% | +16.0% | +2.7% | +12.5% | +6.2% | -0.1% | -0.9% | -1.0% | +26.9% | -7.8% | -12.3% | |
| – | -53.6% | +50.8% | +46.5% | -51.1% | -32.4% | +100.8% | -45.0% | -22.2% | +20.9% | +60.4% | +7.2% | |
| – | +1.2% | +0.8% | +0.8% | +0.9% | -33.9% | +5.2% | +1.3% | +1.8% | -4.7% | +42.2% | +14.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +18.5% | +13.9% | +2.1% | +1.6% | +5.2% | +16.1% | +4.1% | +6.6% | +4.6% | +3.8% | +2.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.